- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00365612
Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients
April 9, 2008 updated by: Gilead Sciences
Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on Their HAART Regimen
To compare the effectiveness (efficacy, safety & tolerability) of a Single Tablet Regimen of efavirenz/emtricitabine/tenofovir DF to subjects continuing on unmodified HAART as measured by the proportion of patients who maintain viral load (HIV-1 RNA) <200 copies/mL at Week 48.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
300
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ponce, Puerto Rico, 00731
-
San Juan, Puerto Rico, 00909
-
-
-
-
Alabama
-
Hobson City, Alabama, United States, 36201
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
-
-
California
-
Beverly HIlls, California, United States, 90211
-
Long Beach, California, United States, 90813
-
Los Angeles, California, United States, 90069
-
Oakland, California, United States, 94609
-
San Diego, California, United States, 92103
-
San Francisco, California, United States, 94114
-
Tarzana, California, United States, 91356
-
-
Colorado
-
Denver, Colorado, United States, 80220
-
-
Connecticut
-
Norwalk, Connecticut, United States, 06851
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
-
-
Florida
-
Ft. Lauderdale, Florida, United States, 33308
-
Hollywood, Florida, United States, 33020
-
Miami, Florida, United States, 33136
-
Orlando, Florida, United States, 32803
-
Pensacola, Florida, United States, 32504
-
Port St Lucie, Florida, United States, 34952
-
Safety Harbor, Florida, United States, 34695
-
Tampa, Florida, United States, 33607
-
Vero Beach, Florida, United States, 32960
-
-
Georgia
-
Atlanta, Georgia, United States, 30312
-
Decatur, Georgia, United States, 30033
-
-
Illinois
-
Aurora, Illinois, United States, 60505
-
Chicago, Illinois, United States, 60657
-
-
Indiana
-
Indianapolis, Indiana, United States, 46280
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02030
-
Springfield, Massachusetts, United States, 01107
-
-
Michigan
-
Berkley, Michigan, United States, 48072
-
Grosse Pointe Woods, Michigan, United States, 48236
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
-
-
Missouri
-
St. Louis, Missouri, United States, 63139
-
-
New Jersey
-
Hillsborough, New Jersey, United States, 08844
-
Newark, New Jersey, United States, 07102
-
Newark, New Jersey, United States, 07101
-
Somers Point, New Jersey, United States, 08244
-
-
New York
-
Albany, New York, United States, 12208
-
Brooklyn, New York, United States, 11203
-
Mount Vernon, New York, United States, 10550
-
New York, New York, United States, 10011
-
Rochester, New York, United States, 14604
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28209
-
Greenville, North Carolina, United States, 27858
-
Winston-Salem, North Carolina, United States, 27157
-
-
Ohio
-
Akron, Ohio, United States, 44304
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
-
-
Texas
-
Dallas, Texas, United States, 75204
-
Harlingen, Texas, United States, 78550
-
Houston, Texas, United States, 77009
-
-
Virginia
-
Annandale, Virginia, United States, 22003
-
Hampton, Virginia, United States, 23666
-
-
Washington
-
Spokane, Washington, United States, 99204
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HIV-1 positive patients who have maintained an HIV-1 viral load <200 copies/mL, for at least 3 months.
- Patients must be on their first HAART or have documented viral suppression on a PI-based regimen at the time of any prior change in therapy.
HAART must consist of either:
- A PI (with or without ritonavir) + at least 2 NRTIs or
- An NNRTI + at least 2 NRTIs.
- Negative serum pregnancy test.
Exclusion Criteria:
- Patients who have taken any NNRTI prior to their current therapy.
- Patients who have taken a NRTI-only therapy for greater than 7 days prior to their current therapy.
- Patients who are currently taking EFV+FTC+TDF.
- Patients who have a creatinine clearance of <60 mL/min by Cockcroft-Gault estimation.
- Patients who have experienced virologic failure with any previous ARV therapy.
- Patients who have documented resistance to any of the study agents at any time in the past.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Primary: Proportion of patients with HIV-1 RNA levels <200 copies/mL at Week 48
|
|
Safety Outcome Measures: Adverse Events, Laboratory Tests
|
|
Outcomes Research Measures: Quality of life, adherence, preference of medication, perceived ease of regimen, HIV symptoms
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: John Flaherty, Gilead Sciences
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF; AI266073 Study Group. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS. 2010 Feb;24(2):87-96. doi: 10.1089/apc.2009.0259.
- Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A; AI266073 Study Group. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74. doi: 10.1097/QAI.0b013e3181a572cf.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2006
Primary Completion (Actual)
October 1, 2007
Study Completion (Actual)
January 1, 2008
Study Registration Dates
First Submitted
August 16, 2006
First Submitted That Met QC Criteria
August 16, 2006
First Posted (Estimate)
August 17, 2006
Study Record Updates
Last Update Posted (Estimate)
April 10, 2008
Last Update Submitted That Met QC Criteria
April 9, 2008
Last Verified
April 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Tenofovir
- Emtricitabine
- Efavirenz
Other Study ID Numbers
- AI266073
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.